Table 3. Main differential characteristics of the study population according to the results of HC2 and Pap smear.
| Characteristic | HPV− (HR) n (%) | HPV+ (HR) n(%) | p-value * | Pap smear normal n (%) | Pap smear ** abnormal n (%) | p-value * |
| Age (years) | ||||||
| <30 | 15 (4.7) | 22 (13.8) | 0.001 | 25 (6.3) | 12 (14.3) | 0.05 |
| 30–40 | 107 (33.4) | 57 (35.8) | 137 (34.7) | 27 (32.1) | ||
| >40 | 198 (61.9) | 80 (50.4) | 233 (59.0) | 45 (53.6) | ||
| Marital status | ||||||
| No stable partner | 163 (51.3) | 93 (58.9) | 0.117 | 198 (50.4) | 58 (69.9) | <0.01 |
| Stable partner | 155 (48.7) | 65 (41.1) | 195 (49.6) | 25 (30.1) | ||
| Age at first sexual intercourse (years) | ||||||
| ≤18 | 249 (78.1) | 130 (82.3) | 0.280 | 308 (78.2) | 71 (85.5) | 0.131 |
| >18 | 70 (21.9) | 28 (17.7) | 86 (21.8) | 12 (14.5) | ||
| Number of sexual partners to date | ||||||
| ≤5 | 174 (54.7) | 82 (52.9) | 0.821 | 219 (55.7) | 37 (46.2) | 0.343 |
| 06-oct | 49 (15.4) | 27 (17.4) | 63 (16.0) | 13 (16.3) | ||
| nov-20 | 52 (16.4) | 22 (14.2) | 57 (14.6) | 17 (21.3) | ||
| >20 | 43 (13.5) | 24 (15.5) | 54 (13.7) | 13 (16.2) | ||
| Number of sexual partners during the last 6 months | ||||||
| None | 84 (26.9) | 43 (27.9) | 0.500 | 104 (26.9) | 23 (29.1) | 0.004 |
| 1 | 210 (67.3) | 98 (63.6) | 262 (67.7) | 46 (58.2) | ||
| >1 | 18 (5.8) | 13 (8.5) | 21 (5.4) | 10 (12.7) | ||
| Use of condom (stable partner) § | ||||||
| Always | 117 (57.6) | 58 (61.1) | 0.460 | 148 (58.7) | 27 (58.7) | 0.547 |
| Sometimes | 49 (24.2) | 17 (17.9) | 58 (23.0) | 8 (17.4) | ||
| Never | 37 (18.2) | 20 (21.0) | 46 (18.3) | 11 (23.9) | ||
| Use of condom (casual partner) § | ||||||
| Always | 26 (65.0) | 13 (61.9) | 0.820 | 28 (60.8) | 11 (73.3) | 0.491 |
| Sometimes | 7 (17.5) | 3 (14.3) | 9 (19.6) | 1 (6.7) | ||
| Never | 7 (17.5) | 5 (23.8) | 9 (19.6) | 3 (20.0) | ||
| Time since oral contraceptives were last taken (years) | ||||||
| <1 | 8 (3.8) | 10 (10.0) | 0.005 | 12 (4.9) | 6 (9.8) | 0.238 |
| 01-maig | 15 (7.2) | 17 (17.0) | 23 (9.3) | 9 (14.8) | ||
| 06-oct | 32 (15.4) | 12 (12.0) | 37 (15.0) | 7 (11.5) | ||
| >10 | 153 (73.6) | 61 (61.0) | 175 (70.8) | 39 (63.9) | ||
| CD4 T lymphocytes (cells/mm3) | ||||||
| <200 | 16 (5.3) | 27 (17.9) | <0.01 | 23 (6.1) | 20 (25.6) | <0.01 |
| 200–500 | 128 (42.1) | 68 (45.0) | 160 (42.4) | 36 (46.2) | ||
| >500 | 160 (52.6) | 56 (37.1) | 194 (51.5) | 22 (28.2) | ||
| HIV-1 viral load (copies/mL) | ||||||
| <400 | 225 (79.2) | 88 (64.7) | 0.002 | 266 (76.7) | 47 (64.3) | 0.006 |
| 400–5,000 | 28 (9.9) | 17 (12.5) | 37 (10.7) | 8 (11.0) | ||
| 5,000–10,000 | 9 (3.2) | 4 (2.9) | 12 (3.5) | 1 (1.4) | ||
| >10,000 | 22 (7.7) | 27 (19.9) | 32 (9.1) | 17 (23.3) | ||
| Time on treatment (months) | ||||||
| <60 | 74 (26.5) | 65 (48.5) | <0.01 | 100 (29.5) | 39 (52.7) | <0.01 |
| 60–120 | 107 (38.4) | 32 (23.9) | 129 (38.1) | 10 (13.5) | ||
| >120 | 98 (35.1) | 37 (27.6) | 110 (32.4) | 25 (33.8) |
*
X2 test for linear trend.
**
(low-grade squamous intraepithelial lesion and high grade squamous intraepithelial lesion).
§
during the last 6 months.